What is MET233 and MET097 used for?

MET233 and MET097 is indicated for Indication 1, Indication 2.

Who makes MET233 and MET097?

MET233 and MET097 is developed by Pfizer.

What development phase is MET233 and MET097 in?

MET233 and MET097 is FDA-approved (marketed).

What is the generic name of MET233 and MET097?

met233-and-met097 is the generic (nonproprietary) name of MET233 and MET097.

Last reviewed 2026-04-20 · How we verify

MET233 and MET097 (met233-and-met097)

Pfizer · FDA-approved active Quality 22/100

MET233 and MET097, developed by Pfizer Inc., are marketed drugs with a revenue of $21.2B. They are used to treat Indication 1 and Indication 2. The drugs have undergone 1 trial and have 0 publications. Their mechanism of action is not specified on Wikipedia.

At a glance

Generic name	met233-and-met097
Sponsor	Pfizer
Drug class	Not specified
Target	Not specified
Therapeutic area	Other
Phase	FDA-approved

Approved indications

Indication 1
Indication 2

Common side effects

No common side effects on file.

Drug interactions

Warfarin
Aspirin
Clopidogrel
Pentoxifylline
Dipyridamole
Alteplase
Reteplase
Tenecteplase
Urokinase
Streptokinase
Abciximab
Eptifibatide

Key clinical trials

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MET233 and MET097 CI brief — competitive landscape report
MET233 and MET097 updates RSS · CI watch RSS
Pfizer portfolio CI